OnKure Therapeutics, Inc.
- Open
- 4.37
- Day high
- 4.54
- Day low
- 4.35
- Prev close
- 4.34
- Volume
- 40K
- Mkt cap
- $178M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.0
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$2K over the last 3 months (0 open-market buys, 2 sales)
- 🏛Institutions mixed (13F)
OnKure Therapeutics, Inc. (OKUR) is a Healthcare company listed on NASDAQ. The stock is up 70% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 2 sales (SEC Form 4).
OnKure Therapeutics, Inc. (OKUR) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
OKUR earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 5, 2026 | $-0.81 | $-1.11 | -37.0% | — | — |
| Mar 9, 2026 | $-1.15 | $3.40 | +395.1% | — | — |
| Nov 6, 2025 | $-1.20 | $-1.09 | +9.2% | — | — |
| Aug 12, 2025 | $-1.23 | $-1.14 | +7.3% | — | — |
| Mar 10, 2025 | $-0.86 | $-1.37 | -59.3% | — | — |
| Nov 7, 2024 | $-0.97 | $-1.10 | -13.4% | — | — |
| Dec 31, 2023 | $-5.78 | $-7.00 | -21.1% | — | — |
| Sep 30, 2023 | $-5.71 | $-1.44 | +74.8% | — | — |
| Jun 30, 2023 | $-5.30 | $-0.61 | +88.4% | — | — |
OKUR insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 24, 2026 | Leverone Jason A.officer: Chief Financial Officer | Sell | 303 | $4.40 |
| Jun 24, 2026 | Saccomano Nicholas Adirector, officer: President and CEO | Sell | 86 | $4.40 |
| Jun 8, 2026 | Ratcliffe Liamdirector | Grant | 1,275 | $4.30 |
| Jun 8, 2026 | Carruthers R Michaeldirector | Grant | 7,650 | $4.30 |
| Jun 8, 2026 | Phillips Andrew Johndirector | Grant | 7,650 | $4.30 |
| Jun 8, 2026 | Jansen Valerie Malyvanhdirector | Grant | 7,650 | $4.30 |
| Jun 8, 2026 | GREY MICHAEL Gdirector | Grant | 7,650 | $4.30 |
| Jun 8, 2026 | Mathers Edward Tdirector | Grant | 7,650 | $4.30 |
| Apr 3, 2026 | Hartley Dylanofficer: Chief Scientific Officer | Grant | 110,000 | $4.07 |
| Apr 3, 2026 | Agresta Samuelofficer: Chief Medical Officer | Grant | 110,000 | $4.07 |
| Apr 3, 2026 | Saccomano Nicholas Adirector, officer: President and CEO | Grant | 330,000 | $4.07 |
| Apr 3, 2026 | Leverone Jason A.officer: Chief Financial Officer | Grant | 110,000 | $4.07 |
| Apr 1, 2026 | Ratcliffe Liamdirector | Grant | 15,300 | $4.14 |
| Mar 24, 2026 | Leverone Jason A.officer: Chief Financial Officer | Sell | 301 | $4.16 |
| Mar 24, 2026 | Saccomano Nicholas Adirector, officer: President and CEO | Sell | 86 | $4.16 |
Source: OKUR SEC Form 4 filings, latest Jun 24, 2026. For informational purposes only — not investment advice.
See the full OKUR insider & 13F page →OnKure Therapeutics, Inc. company profile
Overview
OnKure Therapeutics, Inc. (NASDAQ:OKUR) is a clinical-stage biotechnology company founded in 2011 and headquartered in Boulder, Colorado. The company specializes in discovering and developing precision oncology medicines, with a particular focus on creating selective inhibitors of histone deacetylases (HDACs) for treating various forms of cancer. OnKure went public through a merger transaction and currently trades on NASDAQ, representing one of the smaller players in the competitive oncology drug development space.
Business
OnKure operates in the biotechnology sector, specifically within the oncology drug development industry. This industry involves the research, development, and commercialization of treatments for cancer, one of the most challenging and lucrative areas of pharmaceutical development. The company's core focus is on developing precision medicines, which are treatments designed to target specific molecular characteristics of individual tumors rather than using broad-spectrum approaches. The company's primary approach centers on histone deacetylase (HDAC) inhibitors. To understand this, it's important to know that histones are proteins that help package DNA in cells, and histone deacetylases are enzymes that modify these proteins. In cancer cells, HDACs often become overactive, leading to the silencing of tumor suppressor genes. HDAC inhibitors work by blocking these enzymes, potentially restoring normal cell function and triggering cancer cell death. OnKure's lead product candidate is OKI-179, a selective HDAC inhibitor designed to treat both hematological cancers (blood cancers like leukemia and lymphoma) and solid tumors (cancers that form masses in organs or tissues). The selectivity aspect is crucial because it means the drug is designed to target specific HDAC enzymes rather than broadly inhibiting all HDACs, which could potentially reduce side effects while maintaining therapeutic efficacy. The company currently operates as a single-segment business focused entirely on oncology drug development, with no commercial revenue as all products remain in clinical development stages.
Revenue model
OnKure currently generates no revenue, as is typical for early-stage biotechnology companies focused on drug development. The company's future business model will likely center on product sales of approved oncology drugs, assuming successful completion of clinical trials and regulatory approval. In the biotechnology industry, companies typically monetize their research through several potential pathways. The primary revenue model would involve direct sales of approved drugs to healthcare providers, hospitals, and specialty pharmacies, who then administer or dispense these treatments to cancer patients. Oncology drugs, particularly precision medicines, typically command premium pricing due to their specialized nature and the high unmet medical need in cancer treatment. Alternative monetization strategies common in biotech include licensing agreements with larger pharmaceutical companies, where OnKure could receive upfront payments, milestone payments during development, and royalties on future sales. The company might also pursue partnership deals for co-development or co-commercialization of their drug candidates. Several factors could significantly impact OnKure's future margins and profitability. Regulatory approval success rates represent the most critical factor, as the vast majority of drug candidates fail during clinical trials. Competition from other oncology treatments, including both existing therapies and other drugs in development, could affect pricing power. Manufacturing costs and scalability will influence gross margins, while the company's ability to achieve market penetration will determine revenue potential. Additionally, healthcare reimbursement policies and insurance coverage decisions will significantly impact the commercial viability of any approved treatments.
Competitive moat
OnKure's competitive moat appears relatively limited at this early stage of development. The company's primary potential advantage lies in its selective HDAC inhibitor approach, which could differentiate OKI-179 from existing HDAC inhibitors that are less selective and potentially more toxic. However, this technological advantage is not yet proven in clinical trials and could be replicated by competitors with sufficient resources. The biotechnology industry offers limited sustainable competitive advantages during the development phase. Patent protection provides temporary exclusivity, but patents eventually expire, and competitors can often develop alternative approaches to target the same biological pathways. OnKure's intellectual property portfolio around HDAC inhibition may provide some protection, but the strength and breadth of these patents are not publicly detailed. The company faces significant competitive threats from multiple directions. Large pharmaceutical companies with substantially greater resources are actively developing oncology treatments, including other HDAC inhibitors and alternative approaches to treating the same cancer types. Academic institutions and other biotech companies are also pursuing similar research directions. Additionally, the rapidly evolving field of immunotherapy and targeted therapy could potentially render HDAC inhibitors less attractive if more effective treatments emerge. OnKure's small size and limited resources compared to major pharmaceutical companies represent a significant competitive disadvantage. The company lacks the financial capacity to pursue multiple drug candidates simultaneously or to conduct large-scale clinical trials that might be necessary for regulatory approval. Without established commercial infrastructure, OnKure would likely need to partner with larger companies for successful drug commercialization, potentially limiting future profit margins.
Risks & safety
OnKure presents a mixed margin of safety profile typical of early-stage biotechnology companies, with strong liquidity but fundamental business risks. • Liquidity position: Strong cash position of $96.7 million as of Q1 2025, providing substantial runway given current burn rates • Debt levels: Minimal debt with debt-to-equity ratio of just 0.01, indicating very low leverage risk • Current ratio: Excellent at 11.17, demonstrating strong ability to meet short-term obligations • Cash burn: Operating cash flow negative $14 million in Q1 2025, suggesting approximately 6-7 quarters of runway at current burn rate • Solvency risk: Low near-term bankruptcy risk due to strong balance sheet, but will require additional funding for continued operations • Valuation metrics: Trading at 0.64 price-to-book ratio, suggesting potential undervaluation relative to net assets • Enterprise value: Negative enterprise value due to cash exceeding market capitalization, indicating potential asset value • Revenue multiple: Not applicable as company generates no revenue • Other considerations: High clinical trial risk as single product candidate could fail, requiring significant additional capital for future development, and potential dilution from future equity raises to fund operations.
Recent development
Based on the available financial data, OnKure appears to have undergone significant corporate restructuring and financing activities over the past few years. The company's balance sheet shows dramatic improvements in its financial position, particularly evident in the substantial increase in cash and short-term investments from approximately $11.5 million at the end of 2022 to over $110 million by the end of 2024. This cash infusion likely resulted from the company's public market transaction, as evidenced by the significant changes in the company's capital structure and the resolution of what appeared to be substantial liabilities in earlier periods. The financial statements show the company had negative shareholders' equity in 2022 and 2023, which was resolved by 2024, suggesting a major recapitalization event. The company has maintained consistent focus on its core HDAC inhibitor program throughout this period, with steady research and development spending as evidenced by the consistent operating cash flow burns. The quarterly burn rate has remained relatively stable in the $13-15 million range, indicating disciplined capital allocation toward advancing OKI-179 through clinical development. OnKure's operational focus appears to have remained steady on advancing its lead compound OKI-179 through clinical trials for both hematological and solid tumor indications. The company's ability to secure substantial funding provides the financial foundation necessary to advance its clinical programs and potentially expand its pipeline, though specific details about clinical trial progress and strategic partnerships are not available from the financial data alone.
OKUR company profile · for informational purposes only — not investment advice.
Track OKUR with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free